Omentin-1 vs Darbepoetin Alfa
Head-to-head comparison of Omentin-1 (Omentin-1 (Intelectin-1, ITLN1)) and Darbepoetin Alfa (Darbepoetin alfa, recombinant human erythropoiesis-stimulating protein) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Omentin-1 | Darbepoetin Alfa |
|---|---|---|
| Category | Diabetes & Metabolic | Muscle & Performance |
| Full Name | Omentin-1 (Intelectin-1, ITLN1) | Darbepoetin alfa, recombinant human erythropoiesis-stimulating protein |
| Molecular Weight | ~35 kDa | ≈37,000 Da |
| Half-Life | hours | ~21 h IV; ~49 h SC |
| Amino Acids | 313 | 165 |
| Typical Dose | No approved human dose; research use only | 0.45 mcg/kg weekly SC or 0.75 mcg/kg every 2 weeks |
| Route | IV|SC | Subcutaneous/IV |
| Purity | ≥98% | ≥98% |
| Studies Count | 82 | 210 |
| Research Status | Pre-clinical | Clinical |
Omentin-1 Benefits
- ✓insulin sensitivity
- ✓glucose uptake
- ✓lipid handling
Darbepoetin Alfa Benefits
- ✓longer-acting erythropoiesis
- ✓stable hemoglobin
- ✓increased oxygen delivery
- ✓may improve aerobic capacity
Omentin-1 Dosing
not established|not established
Darbepoetin Alfa Dosing
0.45 mcg/kg weekly SC|0.75 mcg/kg every 2 weeks SC|Dose-adjust to hemoglobin response
Omentin-1 Side Effects
- ⚠unknown
- ⚠immunogenicity risk
Darbepoetin Alfa Side Effects
- ⚠hypertension
- ⚠thromboembolism
- ⚠headache
Research Overview
Omentin-1
Lower omentin-1 levels are often associated with obesity, insulin resistance, and metabolic syndrome. Research continues on its use as a biomarker and as a mechanistic lead for AMPK-linked metabolic interventions.
Darbepoetin Alfa
Clinical studies show durable hemoglobin correction with less frequent dosing than epoetin alfa. The endurance benefit, where present, would come from improved oxygen-carrying capacity rather than a direct ergogenic pathway.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.